← Back to headlines
Bristol-Myers Squibb Sees Mixed Analyst Sentiment, Cramer Notes Buying Opportunities
Pharmaceutical giant Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment, with Jim Cramer specifically highlighting recent stock pullbacks as excellent buying opportunities despite broader industry momentum.
28 Mar, 20:51 — 28 Mar, 20:51
Sources
Showing 1 of 1 sources
Related Stories
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
2h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
4h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
9h ago
West Nile Virus Outbreaks Spread Across Greece and North Macedonia
9h ago